GlobeNewsWire
02 Sept 2026, 22:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 clinical trial for Fianlimab in combination with Libtayo for melanoma failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a 'potential blockbuster' drug candidate directly eliminates future revenue expectations and has already caused an $11 billion market cap loss.
-0.80A securities class action lawsuit has been filed alleging that Regeneron misled investors regarding the trial's progress and delayed disclosing protocol changes. — Litigation introduces legal liability, potential settlement costs, and reputational damage to management's credibility.
-0.40The lawsuit claims Regeneron was aware that preliminary statistical assumptions were flawed and that meaningful differentiation over standard therapies was not being achieved. — If proven, this suggests systemic issues in the company's clinical reporting and internal transparency.
-0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a securities class action lawsuit following the failure of a Phase 3 clinical trial and a resulting $11 billion market cap loss.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
39m ago
